PHA Pharmagest Interactive SA

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division

Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET)

Press Release

Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division

He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division.

***

(Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of François-Pierre MARQUIER, who is resuming his operational duties as Director of the Pharmagest Division.

The appointment of François-Pierre MARQUIER, proposed by Denis SUPPLISSON, Chief Executive Officer of the Equasens Group, will be effective after a transition period. It was approved by the Board of Directors at its meeting on June 25, 2025, chaired by Thierry CHAPUSOT, Chairman of the Board of Directors.

François-Pierre MARQUIER, who joined Pharmagest in May 2021 as Regional Director for the Ile-de-France region, has headed the Pharmacy France business since January 2023. He will now oversee all the Division's activities, both in France and the rest of Europe.

Denis SUPPLISSON, Chief Executive Officer of Equasens Group, states: « François-Pierre has a deep understanding of our business sectors, a precise grasp of our challenges and the sectoral expertise we need to accelerate our European development. »

Biography François-Pierre MARQUIER -  - Graduate of IDRAC Business School and Emlyon Business School (DUA), he began his career in 1996 with DHL as Marketing Manager. In 2000, he joined Cegid Group where he evolved for over 20 years, holding management positions in marketing and sales.

He joined Equasens Group in May 2021 as Regional Director, before being appointed Director of the Pharmacy France business in January 2023.

He has represented Pharmagest within FEIMA for over 2 years.

Upcoming financial communications

  • 31 July 2025:                 Q2 2025 revenue - After the close of trading
  • 26 September 2025:         H1 2025 results

About - Follow us also on

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.400 people across Europe.

Equasens Group’s specialized business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Listed on Euronext Paris, Equasens Group (Compartment B - FR 0012882389 – $EQS) applies a two-pronged development strategy combining organic growth with targeted acquisitions at a European level.

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel: +33 (0)3 83 15 90 67 -

Financial communications agency:

FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 –

Attachment



EN
03/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of Fran...

 PRESS RELEASE

EQUASENS : Nomination à la direction de la Division Pharmagest

EQUASENS : Nomination à la direction de la Division Pharmagest Villers-lès-Nancy, le 03 juillet 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Equasens annonce le départ de Damien VALICON, Directeur Général Délégué et Directeur de la Division PHARMAGEST Il sera remplacé par François-Pierre MARQUIER en tant que Directeur de la Division Pharmagest *** (Euronext Paris™ - Compartiment B - FR 0012882389 –$EQS), annonce le départ de Damien VALICON, qui occupait depuis 18 mois les fonctions de Directeur Général Délégué du Groupe et de Directeur de la Division PHARMAGEST, ainsi que la nomination de...

 PRESS RELEASE

Equasens: General meeting - Results of the votes

Equasens: General meeting - Results of the votes          Villers-lès-Nancy, 1st July 2025 – 07:00 p.m. (CET) PRESS RELEASE RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2025 Number of shares comprising the share capital: 15,174,125 Number of shares with voting rights: 14,830,415 Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125 That means a quorum of 88.83% of the 14,830,415 shares with voting rights: the Ordinary Annual General Meeting was able to deli...

 PRESS RELEASE

EQUASENS : Assemblée Générale - Résultats des votes

EQUASENS : Assemblée Générale - Résultats des votes Villers-lès-Nancy, le 1er juillet 2025 – 19 :00 (CET) COMMUNIQUE DE PRESSE RESULTAT DU VOTE DES RESOLUTIONS PRESENTEES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE DU 25 JUIN 2025 Nombre d’actions composant le capital social : 15.174.125        Nombre d’actions ayant le droit de participer au vote : 14.830.415 Nombre d’actions, ayant droit de vote, possédées par les actionnaires présents ou représentés ou ayant voté par correspondance : 13.173.125 Soit un quorum de 88,83% des 14.830.415 actions ayant le droit de participer au vote : l...

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - Acquisitions : Renforcement d'Axigate / Achat - Obj :...

Acquisition de Novaprove, éditeur du logiciel ResUrgences Reprise du fonds de commerce de l’activité DIS CA annuel 5 M€ - 300 clients

ResearchPool Subscriptions

Get the most out of your insights

Get in touch